Wire · opportunities
FDA Approves Lirafugratinib for Advanced Bile Duct Cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 September 2026 · Fusion42 review
The FDA has approved lirafugratinib, an oral kinase inhibitor, for adults with previously treated, unresectable, locally advanced, or metastatic cholangiocarcinoma with FGFR2 gene fusion or rearrangement, based on REFOCUS trial results showing tumour shrinkage in 46% of patients. This is the first novel cancer drug developed by a South Korean company to receive FDA approval, marking a significant milestone.
This Wire brief sits within Fusion42's coverage of Biotech, and 10 sources have reported it between 16 Sep 2026 and 5 Oct 2026.
◆ ◆ The Wire takeaway
You can now position your cancer drug to compete on precision targeting of FGFR2 mutations as the FDA clears a new treatment for advanced bile duct cancer. This approval opens a new access route for drugs with sustained efficacy against resistance mutations in a hard-to-treat cancer.
◆ Coverage
10 sources · first reported 16 Sep 2026 · latest 5 Oct 2026
◆ Topics